Drugs / BGB-21447
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06756932 | Feb 2025 → Jul 2027 expected | hormone receptor-positive breast cancer | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1 | NCT05828589 | Jun 2023 → Jun 2026 | Richter transformation, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma +1 | BeOne Medicines | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGB-21447 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06756932 ↗ |
| Action | Inhibit | “A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies” NCT05828589 ↗ |
| Route | Oral | “BGB-21447 will be administered orally” NCT05828589 ↗ |
| Target | BCL2 | “A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies” NCT05828589 ↗ |